Hub : Traits :

Medication: Blood pressure

177 significantly associated models · 71 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	5611729	7460433	3	1	9.8e-09	1.8e-08	2.9e-01	96	DNAJC11
2	1	11060075	12600396	3	1	1.3e-14	3.0e-13	2.4e-02	90	CLCN6
3	1	112312154	113743567	3	2	5.6e-10	3.0e-13	1.5e-07	48	CTTNBP2NL RHOC
4	3	26563909	28211713	2	1	2.5e-14	6.9e-15	5.1e-02	94	SLC4A7
5	3	47681881	49365269	5	1	1.3e-08	9.4e-08	1.0e+00	100	ZNF589
6	4	80407869	82578407	2	2	2.9e-09	1.2e-36	8.9e-26	31	C4orf22 PRDM8
7	4	103020804	104627833	4	1	4.0e-08	5.6e-08	1.0e+00	100	CISD2
8	7	6502367	7988091	1	1	1.6e-07	2.2e-05	3.8e-01	96	C1GALT1
9	10	60026425	60829144	1	1	7.6e-08	2.0e-06	2.9e-01	95	BICC1
10	10	95379543	96818402	1	1	7.8e-08	7.2e-08	1.9e-02	81	NOC3L
11	10	115555541	116053000	1	1	7.5e-08	2.5e-06	6.1e-02	84	ADRB1
12	11	1625363	2161858	1	1	7.4e-09	2.6e-10	8.8e-03	83	LSP1
13	11	46543524	48783497	8	3	2.1e-09	7.2e-11	5.4e-03	82	ACP2 AGBL2 NUP160
14	11	99859184	101559718	2	1	2.0e-17	9.3e-17	1.0e+00	100	ARHGAP42
15	11	110721187	112287801	2	1	4.3e-09	2.7e-09	1.0e+00	100	SIK2
16	12	89286081	90799212	2	2	8.3e-10	1.6e-12	6.6e-06	59	ATP2B1 LOC338758
17	12	111154626	113517494	4	1	3.2e-12	1.4e-18	1.7e-08	59	SH2B3
18	13	114302502	115106996	2	1	1.7e-07	3.7e-07	1.0e+00	100	CDC16
19	15	74042497	75930199	8	1	3.7e-11	5.5e-11	1.0e+00	100	CSK
20	15	80743350	81292020	1	1	7.0e-09	5.5e-10	9.9e-03	83	FAM108C1
21	15	90712555	92135418	2	1	2.1e-21	6.8e-17	9.5e-01	100	FES
22	16	89462678	89961957	1	1	2.1e-07	4.3e-06	8.6e-01	100	CHMP1A
23	17	46258510	47718188	4	2	6.4e-09	3.4e-12	1.0e-05	60	SNF8 ZNF652
24	17	60858059	62259376	2	1	1.9e-10	7.4e-10	1.0e+00	100	ACE
25	20	7419920	9648826	1	2	6.4e-10	3.0e-19	2.2e-07	67	PLCB1
26	20	30083621	31469577	1	1	2.9e-09	1.4e-07	1.1e-05	30	TSPY26P
27	20	57525478	58079512	1	1	2.9e-08	9.5e-13	4.7e-06	59	ZNF831
28	21	44251223	45879403	2	1	2.3e-09	1.0e-08	1.2e-01	92	HSF2BP

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Hypertension (Self-reported)	21.81	34	30	66.7	0.98	9.1e-26	ACE ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CDC16 CHMP1A CISD2 CLCN6 CSK CTTNBP2NL DNAJC11 FAM108C1 FES HSF2BP LOC338758 LSP1 NOC3L NUP160 PLCB1 PRDM8 RHOC SH2B3 SIK2 SLC4A7 SNF8 TSPY26P ZNF589 ZNF652 ZNF831
Systolic Blood Pressure	21.78	32	29	64.4	0.94	4.0e-16	ACE ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CDC16 CHMP1A CLCN6 CSK CTTNBP2NL DNAJC11 FAM108C1 FES HSF2BP LOC338758 LSP1 NOC3L NUP160 PLCB1 PRDM8 RHOC SH2B3 SIK2 SLC4A7 SNF8 ZNF589 ZNF652 ZNF831
High blood pressure	21.48	34	30	66.7	0.98	1.4e-25	ACE ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CDC16 CHMP1A CISD2 CLCN6 CSK CTTNBP2NL DNAJC11 FAM108C1 FES HSF2BP LOC338758 LSP1 NOC3L NUP160 PLCB1 PRDM8 RHOC SH2B3 SIK2 SLC4A7 SNF8 TSPY26P ZNF589 ZNF652 ZNF831
Vascular/heart problems diagnosed by doctor	21.01	34	29	64.4	-0.98	4.2e-25	ACE ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CDC16 CHMP1A CISD2 CLCN6 CSK CTTNBP2NL DNAJC11 FAM108C1 FES HSF2BP LOC338758 LSP1 NOC3L NUP160 PLCB1 PRDM8 RHOC SH2B3 SIK2 SLC4A7 SNF8 TSPY26P ZNF589 ZNF652 ZNF831
Cardiovascular Disease	20.17	34	31	68.9	0.98	1.6e-24	ACE ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CDC16 CHMP1A CISD2 CLCN6 CSK CTTNBP2NL DNAJC11 FAM108C1 FES HSF2BP LOC338758 LSP1 NOC3L NUP160 PLCB1 PRDM8 RHOC SH2B3 SIK2 SLC4A7 SNF8 TSPY26P ZNF589 ZNF652 ZNF831
Medication: Blood pressure	15.44	25	16	35.6	0.98	1.2e-17	ACE ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CHMP1A CISD2 CLCN6 CSK CTTNBP2NL FAM108C1 FES LSP1 PLCB1 RHOC SH2B3 SIK2 SLC4A7 ZNF589 ZNF652 ZNF831
Medication for cholesterol, blood pressure or diabetes	14.81	28	12	26.7	-0.99	2.7e-26	ACE ACP2 ARHGAP42 ATP2B1 C1GALT1 C4orf22 CDC16 CISD2 CLCN6 CSK CTTNBP2NL DNAJC11 FAM108C1 FES HSF2BP LOC338758 NOC3L PLCB1 PRDM8 RHOC SH2B3 SIK2 SLC4A7 SNF8 TSPY26P ZNF589 ZNF652 ZNF831
Systolic blood pressure, automated reading	13.94	23	19	42.2	0.97	6.3e-14	ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CDC16 CLCN6 CSK DNAJC11 FAM108C1 FES LOC338758 LSP1 NOC3L NUP160 RHOC SH2B3 SLC4A7 ZNF589 ZNF831
Diastolic blood pressure, automated reading	13.06	25	18	40.0	0.96	2.8e-14	ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 C1GALT1 C4orf22 CDC16 CHMP1A CISD2 CLCN6 CSK FAM108C1 FES LOC338758 LSP1 NOC3L NUP160 RHOC SH2B3 SIK2 SNF8 ZNF589 ZNF652 ZNF831
Medication: Bendroflumethiazide	11.91	22	8	17.8	0.97	9.5e-15	ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 CHMP1A CLCN6 CSK CTTNBP2NL FAM108C1 FES LOC338758 LSP1 NUP160 PLCB1 RHOC SH2B3 SIK2 SLC4A7 ZNF831
Medication: Amlodipine	10.40	13	6	13.3	0.87	9.4e-05	ACP2 AGBL2 ARHGAP42 ATP2B1 CLCN6 CTTNBP2NL FAM108C1 FES LSP1 NOC3L RHOC SLC4A7 TSPY26P
High blood pressure (mother)	8.90	12	1	2.2	0.98	3.9e-08	ADRB1 ARHGAP42 C4orf22 CHMP1A CLCN6 DNAJC11 FES LSP1 RHOC SLC4A7 SNF8 ZNF831
Illnesses of father: High blood pressure	8.67	13	1	2.2	0.98	3.2e-10	ACE ARHGAP42 ATP2B1 BICC1 C4orf22 CDC16 CHMP1A CLCN6 FES LSP1 NUP160 PLCB1 SH2B3
High blood pressure (siblings)	8.37	11	2	4.4	0.99	4.1e-10	ADRB1 AGBL2 ARHGAP42 BICC1 C1GALT1 CLCN6 FES HSF2BP LSP1 RHOC SH2B3
Medication for cholesterol	8.33	15	3	6.7	-0.98	3.1e-11	ACE ADRB1 ARHGAP42 C4orf22 CHMP1A CISD2 CLCN6 FAM108C1 FES LSP1 PLCB1 RHOC SH2B3 TSPY26P ZNF831
Medication: Lisinopril	8.15	10	0	0.0	0.98	4.8e-07	AGBL2 ARHGAP42 C4orf22 CHMP1A CSK LSP1 SH2B3 SLC4A7 ZNF589 ZNF831
Medication: Atenolol	7.95	8	2	4.4	0.99	4.7e-07	ADRB1 ARHGAP42 C1GALT1 C4orf22 CLCN6 FES RHOC SH2B3
Medication: Ramipril	7.26	7	2	4.4	0.99	4.0e-05	ARHGAP42 CISD2 CSK FES LSP1 NUP160 ZNF652
Number of treatments/medications taken	6.58	11	5	11.1	0.95	6.8e-06	ACE ARHGAP42 C1GALT1 CISD2 FAM108C1 FES RHOC SH2B3 TSPY26P ZNF652 ZNF831
Blood Eosinophil Count	6.51	8	4	8.9	0.70	5.3e-02	AGBL2 CDC16 HSF2BP SH2B3 SIK2 TSPY26P ZNF652 ZNF831
Number of self-reported non-cancer illnesses	6.08	6	4	8.9	0.98	5.8e-04	C1GALT1 CISD2 CLCN6 SH2B3 ZNF652 ZNF831
Illnesses of mother	5.91	7	1	2.2	-0.99	5.1e-05	ADRB1 ARHGAP42 FES LSP1 NUP160 SNF8 ZNF652
Medication: Aspirin	5.74	4	1	2.2	1.00	2.0e-04	FES PRDM8 SIK2 SNF8
Illnesses of siblings	5.56	6	1	2.2	-0.99	5.7e-05	ARHGAP42 C1GALT1 CLCN6 FES SH2B3 ZNF589
Medication: Aspirin	5.54	6	1	2.2	0.99	6.0e-05	FES PRDM8 SH2B3 SIK2 SNF8 ZNF589
Tanning	5.45	5	2	4.4	-0.19	7.6e-01	CHMP1A CLCN6 CSK SH2B3 TSPY26P
Medication: Cholesterol lowering	5.35	8	1	2.2	0.99	1.5e-06	ARHGAP42 C1GALT1 CLCN6 CSK DNAJC11 FES SIK2 ZNF831
Medication: Simvastatin	4.71	4	1	2.2	0.97	3.3e-02	ARHGAP42 DNAJC11 FES ZNF831
Illnesses of father: None of the above (group 1)	4.35	3	1	2.2	0.00	1.0e+00	CDC16 FES SH2B3
Hypothyroidism (self reported)	4.15	2	1	2.2	0.00	1.0e+00	SH2B3 ZNF589
Birth weight of first child	3.84	4	3	6.7	-0.99	1.1e-02	CLCN6 CSK FES SH2B3
Angina	3.68	3	2	4.4	0.00	1.0e+00	FES TSPY26P ZNF652
Angina (self-reported)	3.67	3	1	2.2	0.00	1.0e+00	FES TSPY26P ZNF652
Breast Cancer	3.64	6	2	4.4	0.40	4.3e-01	CSK FES HSF2BP LSP1 SIK2 SLC4A7
Hypothyroidism/myxoedema (self-reported)	3.60	1	1	2.2	0.00	1.0e+00	SH2B3
Hair Pigment	3.52	11	8	17.8	0.26	4.4e-01	ACP2 AGBL2 ARHGAP42 ATP2B1 C4orf22 CDC16 CHMP1A FES SH2B3 TSPY26P ZNF831
Blood White Count	3.51	10	4	8.9	0.76	6.7e-03	ACE ACP2 AGBL2 ARHGAP42 FES NUP160 PLCB1 SH2B3 ZNF589 ZNF652
HDL Cholesterol	3.48	3	2	4.4	0.00	1.0e+00	ACP2 ADRB1 AGBL2
Medication: Levothyroxine sodium	3.40	1	1	2.2	0.00	1.0e+00	SH2B3
Heart attack	3.25	4	1	2.2	0.99	1.5e-02	FES SH2B3 ZNF652 ZNF831
Heart attack/myocardial infarction (self-reported)	3.22	4	1	2.2	0.98	1.6e-02	FES SH2B3 ZNF652 ZNF831
Illnesses of father: Heart disease	3.16	3	1	2.2	0.00	1.0e+00	FES SH2B3 SIK2
Taking other prescription medications	3.15	4	2	4.4	0.99	9.2e-03	CISD2 SH2B3 TSPY26P ZNF652
Hair/balding pattern: Pattern 4	3.15	3	1	2.2	0.00	1.0e+00	C4orf22 FES PRDM8
Allergy	3.05	5	2	4.4	0.10	8.7e-01	CISD2 CLCN6 FES SIK2 ZNF652
Birth weight	2.85	4	4	8.9	-0.63	3.7e-01	ADRB1 FES SH2B3 SIK2
Father's age at death	2.77	4	2	4.4	-0.99	1.3e-02	CSK FES NOC3L SH2B3
Asthma (self-reported)	2.76	2	2	4.4	0.00	1.0e+00	SIK2 ZNF652
Asthma	2.75	2	2	4.4	0.00	1.0e+00	SIK2 ZNF652
Hair/balding pattern: Pattern 3	2.69	2	1	2.2	0.00	1.0e+00	C4orf22 PRDM8
High cholesterol (Self-reported)	2.67	2	0	0.0	0.00	1.0e+00	ARHGAP42 CLCN6
Medication for pain relief, constipation, heartburn	2.61	4	1	2.2	-0.98	2.5e-02	ACE CISD2 FAM108C1 PRDM8
Fasting Glucose	2.60	3	0	0.0	0.00	1.0e+00	ACP2 AGBL2 CISD2
Hayfever, allergic rhinitis or eczema	2.58	4	2	4.4	-0.53	4.7e-01	CSK HSF2BP SIK2 ZNF652
Overall health rating	2.55	6	1	2.2	0.99	1.0e-04	C1GALT1 CISD2 SNF8 TSPY26P ZNF652 ZNF831
Allergy or Eczema	2.53	8	2	4.4	-0.28	5.0e-01	CISD2 CLCN6 CSK FES HSF2BP SH2B3 SIK2 ZNF652
Had major operations	2.51	2	0	0.0	0.00	1.0e+00	BICC1 ZNF652
Bipolar Disorder or Schizophrenia	2.48	4	1	2.2	-0.25	7.5e-01	CHMP1A CLCN6 CSK FES
Fed-up feelings	2.42	3	1	2.2	0.00	1.0e+00	NUP160 SH2B3 SNF8
Schizophrenia (2018)	2.41	2	1	2.2	0.00	1.0e+00	FES TSPY26P
Hair/balding pattern: Pattern 2	2.34	2	1	2.2	0.00	1.0e+00	C4orf22 PRDM8
Mean time to correctly identify matches	2.34	2	1	2.2	0.00	1.0e+00	FES SH2B3
Schizophrenia (2014)	2.21	3	1	2.2	0.00	1.0e+00	CHMP1A CISD2 FES
Coronary Artery Disease (CAD)	2.18	1	0	0.0	0.00	1.0e+00	SH2B3
Pulse wave Arterial Stiffness index	2.17	2	0	0.0	0.00	1.0e+00	CLCN6 FES
Diabetes diagnosed by doctor	2.16	2	0	0.0	0.00	1.0e+00	ACE CISD2
Comparative body size at age 10	2.10	5	2	4.4	0.66	2.3e-01	ACP2 AGBL2 DNAJC11 ZNF589 ZNF652
Pulse wave peak to peak time	2.08	1	0	0.0	0.00	1.0e+00	FES
Type 2 Diabetes (T2D) (2018)	2.07	4	0	0.0	0.99	7.6e-03	ACE C1GALT1 SH2B3 SNF8
Respiratory disease	2.03	3	1	2.2	0.00	1.0e+00	FES SIK2 ZNF652
Lung FEV1/FVC ratio	2.03	7	7	15.6	-0.23	6.3e-01	ARHGAP42 ATP2B1 C1GALT1 CTTNBP2NL DNAJC11 TSPY26P ZNF652
Wheeze or whistling in the chest in last year	1.98	2	0	0.0	0.00	1.0e+00	SIK2 ZNF652
Heart disease (siblings)	1.98	1	0	0.0	0.00	1.0e+00	FES
Blood Red Count	1.97	10	4	8.9	0.49	1.5e-01	BICC1 C4orf22 CHMP1A CLCN6 CSK FES HSF2BP NUP160 SH2B3 ZNF589
Diabetes (self-reported)	1.96	2	0	0.0	0.00	1.0e+00	ACE C1GALT1
Number of operations (self-reported)	1.95	1	0	0.0	0.00	1.0e+00	PRDM8
Depressed Affect (Nagel 2018)	1.94	2	1	2.2	0.00	1.0e+00	NUP160 SH2B3
Reaction Time	1.93	1	1	2.2	0.00	1.0e+00	SH2B3
Past tobacco smoking	1.91	2	0	0.0	0.00	1.0e+00	SH2B3 ZNF652
Primary Biliary Cirrhosis	1.90	2	1	2.2	0.00	1.0e+00	CISD2 SH2B3
Type 2 Diabetes (T2D) (2012)	1.89	1	0	0.0	0.00	1.0e+00	CISD2
Impedance of leg (left)	1.88	7	3	6.7	-0.08	8.7e-01	ARHGAP42 FAM108C1 FES NOC3L RHOC SIK2 ZNF652
Body fat percentage	1.88	8	1	2.2	0.32	4.4e-01	ACP2 C4orf22 DNAJC11 FAM108C1 NOC3L NUP160 SLC4A7 SNF8
Loneliness, isolation	1.88	2	1	2.2	0.00	1.0e+00	NUP160 SH2B3
Leg fat percentage (left)	1.88	6	1	2.2	0.99	2.3e-04	ACP2 C1GALT1 DNAJC11 FAM108C1 NOC3L SNF8
Trunk fat percentage	1.87	7	1	2.2	0.48	2.7e-01	ACP2 CDC16 DNAJC11 FAM108C1 NOC3L NUP160 SNF8
Leg fat percentage (right)	1.86	6	1	2.2	0.69	1.3e-01	ACP2 CLCN6 DNAJC11 FAM108C1 NOC3L SNF8
Heel T-Score	1.85	10	6	13.3	0.02	9.6e-01	ACP2 AGBL2 ARHGAP42 BICC1 CTTNBP2NL DNAJC11 LOC338758 NUP160 RHOC SLC4A7
Neuroticism	1.85	1	1	2.2	0.00	1.0e+00	NUP160
Impedance of leg (right)	1.84	6	3	6.7	-0.06	9.1e-01	ARHGAP42 FAM108C1 FES NOC3L SIK2 ZNF652
Arm fat percentage (right)	1.84	5	2	4.4	0.63	2.5e-01	ACP2 DNAJC11 FAM108C1 NUP160 SNF8
Mood swings	1.84	1	1	2.2	0.00	1.0e+00	NUP160
Miserableness	1.83	1	1	2.2	0.00	1.0e+00	NUP160
Sensitivity / hurt feelings	1.81	3	1	2.2	0.00	1.0e+00	CISD2 FES SNF8
Impedance of whole body	1.81	8	3	6.7	-0.49	2.1e-01	ARHGAP42 CISD2 FAM108C1 LSP1 NOC3L SIK2 SLC4A7 ZNF652
Impedance of arm (left)	1.80	8	3	6.7	-0.40	3.3e-01	CISD2 FAM108C1 LSP1 NOC3L SH2B3 SLC4A7 TSPY26P ZNF652
Neuroticism score	1.78	1	1	2.2	0.00	1.0e+00	NUP160
Arm fat percentage (left)	1.77	5	3	6.7	0.65	2.3e-01	ACP2 DNAJC11 FAM108C1 NUP160 SNF8
Breast cancer (self-reported)	1.77	1	0	0.0	0.00	1.0e+00	SLC4A7
Chronic bronchitis/emphysema (mother)	1.76	1	0	0.0	0.00	1.0e+00	SIK2
Bipolar Disorder (2018)	1.74	1	0	0.0	0.00	1.0e+00	CSK
Long-standing illness, disability or infirmity	1.72	1	0	0.0	0.00	1.0e+00	ZNF652
Ever smoked	1.71	3	0	0.0	0.00	1.0e+00	FES SH2B3 ZNF652
BMI	1.70	10	4	8.9	0.45	1.9e-01	ACP2 C4orf22 CISD2 CSK DNAJC11 FAM108C1 NUP160 SNF8 TSPY26P ZNF652
Guilty feelings	1.70	1	0	0.0	0.00	1.0e+00	NUP160
Smoking Status	1.69	3	0	0.0	0.00	1.0e+00	FAM108C1 FES ZNF652
Heel bone mineral density (BMD) T-score, automated (left)	1.69	3	0	0.0	0.00	1.0e+00	ACP2 ARHGAP42 DNAJC11
Hearing difficulty/problems with background noise	1.69	1	0	0.0	0.00	1.0e+00	CSK
Chest pain or discomfort	1.69	1	0	0.0	0.00	1.0e+00	C1GALT1
Impedance of arm (right)	1.68	7	2	4.4	-0.40	3.7e-01	CISD2 FAM108C1 LSP1 NOC3L SH2B3 SLC4A7 ZNF652
Neuroticism (2016)	1.67	1	1	2.2	0.00	1.0e+00	NUP160
Medication: Ventolin 100micrograms inhaler	1.67	1	0	0.0	0.00	1.0e+00	ZNF652
Ever had bowel cancer screening	1.67	1	0	0.0	0.00	1.0e+00	SIK2
Medication: Metformin	1.66	1	0	0.0	0.00	1.0e+00	CISD2
Number of incorrect matches in round	1.66	2	0	0.0	0.00	1.0e+00	FES NUP160
Peak expiratory flow (PEF)	1.66	1	0	0.0	0.00	1.0e+00	C1GALT1
Chronotype (morning person)	1.65	1	0	0.0	0.00	1.0e+00	ACP2
Age when periods started (menarche)	1.65	2	0	0.0	0.00	1.0e+00	CDC16 FAM108C1
Forced expiratory volume in 1-second (FEV1)	1.63	6	1	2.2	-0.98	4.4e-04	ACP2 ARHGAP42 C1GALT1 CDC16 RHOC TSPY26P
Ever highly irritable/argumentative for 2 days	1.63	1	0	0.0	0.00	1.0e+00	LSP1
Headache pain in last month	1.63	2	0	0.0	0.00	1.0e+00	CISD2 FES
Neuroticism (Nagel 2018)	1.61	1	1	2.2	0.00	1.0e+00	NUP160
Hayfever/allergic rhinitis (self-reported)	1.60	1	0	0.0	0.00	1.0e+00	HSF2BP
Smoking status: Previous	1.60	1	0	0.0	0.00	1.0e+00	SH2B3
Forced expiratory volume in 1-second (FEV1), Best measure	1.59	6	0	0.0	-0.98	6.3e-04	ACP2 ARHGAP42 C1GALT1 CDC16 RHOC TSPY26P
Diabetes (father)	1.58	1	0	0.0	0.00	1.0e+00	SNF8
Trunk fat mass	1.58	4	1	2.2	0.65	3.5e-01	CDC16 DNAJC11 FAM108C1 SNF8
Frequency of tiredness / lethargy in last 2 weeks	1.58	2	0	0.0	0.00	1.0e+00	NUP160 SNF8
Leg fat mass (left)	1.57	3	2	4.4	0.00	1.0e+00	DNAJC11 FAM108C1 SNF8
Leg fat mass (right)	1.55	3	2	4.4	0.00	1.0e+00	DNAJC11 FAM108C1 SNF8
Osteoarthritis (self-reported)	1.55	2	0	0.0	0.00	1.0e+00	CSK SIK2
Eye problems/disorders: Glaucoma	1.55	2	0	0.0	0.00	1.0e+00	ACP2 AGBL2
Whole body fat mass	1.54	4	1	2.2	0.70	3.0e-01	CDC16 DNAJC11 FAM108C1 SNF8
Suffer from 'nerves'	1.54	1	1	2.2	0.00	1.0e+00	NUP160
Pain experienced in last month	1.53	2	0	0.0	0.00	1.0e+00	FAM108C1 SH2B3
Blood Platelet Count	1.52	8	4	8.9	-0.27	5.1e-01	CSK CTTNBP2NL PLCB1 RHOC SH2B3 SIK2 SLC4A7 SNF8
Medication: Allopurinol	1.52	1	0	0.0	0.00	1.0e+00	SH2B3
Height	1.50	17	14	31.1	-0.54	2.5e-02	ACE ACP2 ADRB1 AGBL2 ARHGAP42 BICC1 CDC16 FES LSP1 NOC3L NUP160 RHOC SH2B3 SLC4A7 SNF8 ZNF652 ZNF831
Heel bone mineral density (BMD) T-score, automated (right)	1.50	3	0	0.0	0.00	1.0e+00	ACP2 ARHGAP42 DNAJC11
Number of live births	1.50	1	0	0.0	0.00	1.0e+00	CISD2
Gout (self-reported)	1.49	1	0	0.0	0.00	1.0e+00	SH2B3
LDL Cholesterol	1.47	2	0	0.0	0.00	1.0e+00	CSK SH2B3
Body mass index (BMI)	1.47	5	2	4.4	0.70	1.9e-01	ACP2 DNAJC11 FAM108C1 NUP160 SNF8
Alzheimer’s Disease (including proxy)	1.45	1	1	2.2	0.00	1.0e+00	ACE
Arm fat mass (right)	1.45	4	2	4.4	0.69	3.1e-01	DNAJC11 FAM108C1 NUP160 SNF8
Mouth/teeth dental problems: Mouth ulcers	1.43	1	0	0.0	0.00	1.0e+00	SH2B3
Supplements: Glucosamine	1.42	1	0	0.0	0.00	1.0e+00	CSK
Waist circumference	1.41	3	1	2.2	0.00	1.0e+00	CSK DNAJC11 FAM108C1
Lupus	1.40	1	0	0.0	0.00	1.0e+00	CSK
Frequency of depressed mood in last 2 weeks	1.40	1	0	0.0	0.00	1.0e+00	NUP160
Forced vital capacity (FVC)	1.40	3	1	2.2	0.00	1.0e+00	ACP2 CDC16 RHOC
Ever taken oral contraceptive pill	1.39	1	0	0.0	0.00	1.0e+00	TSPY26P
Hip circumference	1.38	6	2	4.4	-0.11	8.3e-01	ACP2 CDC16 CLCN6 DNAJC11 FAM108C1 SH2B3
Standing height	1.38	12	8	17.8	-0.43	1.6e-01	ACP2 ADRB1 AGBL2 CDC16 LSP1 NUP160 RHOC SH2B3 SLC4A7 SNF8 ZNF652 ZNF831
Sitting height	1.36	8	4	8.9	-0.02	9.5e-01	ADRB1 CDC16 DNAJC11 HSF2BP NUP160 SLC4A7 ZNF652 ZNF831
Arm fat mass (left)	1.36	4	2	4.4	0.70	3.0e-01	DNAJC11 FAM108C1 NUP160 SNF8
Forced expiratory volume in 1-second (FEV1), predicted	1.34	1	0	0.0	0.00	1.0e+00	CDC16
Age started oral contraceptive pill	1.34	1	0	0.0	0.00	1.0e+00	ZNF652
Comparative height size at age 10	1.31	7	2	4.4	-0.53	2.3e-01	ACP2 AGBL2 C4orf22 CDC16 FAM108C1 FES SH2B3
Forced vital capacity (FVC), Best measure	1.30	3	2	4.4	0.00	1.0e+00	ACP2 CDC16 RHOC
Exposure to tobacco smoke outside home	1.29	1	0	0.0	0.00	1.0e+00	SH2B3
Age at First Birth	1.28	1	0	0.0	0.00	1.0e+00	ZNF652
Breastfed as a baby	1.28	1	0	0.0	0.00	1.0e+00	FES
Medication: Ibuprofen (e.g. Nurofen)	1.25	1	0	0.0	0.00	1.0e+00	CSK
Worry (Nagel 2018)	1.24	1	1	2.2	0.00	1.0e+00	NUP160
Tense / 'highly strung'	1.24	1	0	0.0	0.00	1.0e+00	NUP160
Pulse rate, automated reading	1.23	2	0	0.0	0.00	1.0e+00	C4orf22 SIK2
Blood clot in the leg (DVT)	1.22	1	0	0.0	0.00	1.0e+00	SH2B3
Seen a psychiatrist for nerves, anxiety, tension or depression	1.22	1	0	0.0	0.00	1.0e+00	ADRB1
Medication: Seretide 50 evohaler	1.21	1	0	0.0	0.00	1.0e+00	ZNF652
Stomach or abdominal pain in last month	1.20	1	0	0.0	0.00	1.0e+00	CHMP1A
Arm predicted mass (left)	1.20	4	1	2.2	-0.78	2.2e-01	CDC16 FAM108C1 SH2B3 SLC4A7
Alcohol usually taken with meals	1.18	1	0	0.0	0.00	1.0e+00	FES
Risk taking	1.18	1	0	0.0	0.00	1.0e+00	FES
Nervous feelings	1.17	1	0	0.0	0.00	1.0e+00	NUP160
Weight	1.17	3	2	4.4	0.00	1.0e+00	CDC16 FAM108C1 SH2B3
Arm fat-free mass (left)	1.17	4	1	2.2	-0.82	1.8e-01	CDC16 FAM108C1 SH2B3 SLC4A7
Ulcerative Colitis (UC)	1.16	1	0	0.0	0.00	1.0e+00	CISD2
Verbal and Numeric Reasoning (VNR)	1.14	1	0	0.0	0.00	1.0e+00	ACP2
Trunk fat-free mass	1.14	5	1	2.2	-0.60	2.8e-01	ARHGAP42 CDC16 FAM108C1 SH2B3 SLC4A7
Irritable Bowel Disease (IBD)	1.13	1	0	0.0	0.00	1.0e+00	LSP1
Trunk predicted mass	1.13	5	1	2.2	-0.61	2.7e-01	ARHGAP42 CDC16 FAM108C1 SH2B3 SLC4A7
Arm fat-free mass (right)	1.13	4	1	2.2	-0.76	2.4e-01	CDC16 FAM108C1 SH2B3 SLC4A7
Arm predicted mass (right)	1.13	4	1	2.2	-0.68	3.2e-01	CDC16 FAM108C1 SH2B3 SLC4A7
Alcohol intake frequency.	1.13	1	0	0.0	0.00	1.0e+00	SNF8
Rheumatoid Arthritis	1.12	1	0	0.0	0.00	1.0e+00	SH2B3
Schizophrenia vs Biploar Disorder	1.08	1	0	0.0	0.00	1.0e+00	SNF8
Whole body fat-free mass	1.08	5	1	2.2	-0.59	3.0e-01	ARHGAP42 CDC16 FAM108C1 SH2B3 SLC4A7
Whole body water mass	1.08	5	1	2.2	-0.61	2.8e-01	ARHGAP42 CDC16 FAM108C1 SH2B3 SLC4A7
Leg fat-free mass (right)	1.07	5	2	4.4	-0.74	1.5e-01	ARHGAP42 CDC16 FAM108C1 FES SH2B3
Leg predicted mass (right)	1.07	5	1	2.2	-0.74	1.5e-01	ARHGAP42 CDC16 FAM108C1 FES SH2B3
Intelligence (Savage-Jansen 2018)	1.06	1	0	0.0	0.00	1.0e+00	ACP2
Relative age of first facial hair	1.06	1	1	2.2	0.00	1.0e+00	C4orf22
Hand grip strength (left)	1.05	2	0	0.0	0.00	1.0e+00	FES RHOC
Handedness (chirality/laterality): Left-handed	1.05	1	0	0.0	0.00	1.0e+00	FES
Basal metabolic rate	1.05	3	3	6.7	0.00	1.0e+00	CDC16 FAM108C1 SH2B3
Hand grip strength (right)	1.04	1	0	0.0	0.00	1.0e+00	RHOC
Leg fat-free mass (left)	1.03	5	1	2.2	-0.74	1.5e-01	ARHGAP42 CDC16 FAM108C1 FES SH2B3
Leg predicted mass (left)	1.03	5	1	2.2	-0.73	1.6e-01	ARHGAP42 CDC16 FAM108C1 FES SH2B3
Lung FVC	1.01	5	0	0.0	-0.53	3.6e-01	C1GALT1 CLCN6 CTTNBP2NL SH2B3 TSPY26P
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.00	1	0	0.0	0.00	1.0e+00	C1GALT1
Reproduciblity of spirometry measurement using ERS/ATS criteria	0.97	1	0	0.0	0.00	1.0e+00	CDC16
Average weekly red wine intake	0.97	1	0	0.0	0.00	1.0e+00	CSK
Waist Hip Ratio (WHR)	0.90	2	0	0.0	0.00	1.0e+00	AGBL2 SIK2

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adrenal Gland	2	0.137	1.9
GTEx	Artery Aorta	6	0.202	1.9
GTEx	Artery Tibial	6	0.160	1.9
GTEx	Breast Mammary Tissue (Female)	3	0.182	1.9
GTEx	Cells Transformed fibroblasts	9	0.214	1.9
GTEx	Esophagus Gastroesophageal Junction	2	0.138	1.9
GTEx	Lung	2	0.070	1.9
GTEx	Muscle Skeletal	5	0.173	1.9
GTEx	Ovary	2	0.220	1.9
GTEx	Prostate	0	0.000	1.9
GTEx	Skin Not Sun Exposed Suprapubic	3	0.122	1.9
GTEx	Stomach	1	0.069	1.9
GTEx	Vagina	2	0.315	1.9
ROSMAP	Brain Pre-frontal Cortex	4	0.091	1.9
GTEx	Adipose Subcutaneous	4	0.115	1.8
GTEx	Adipose Visceral Omentum	3	0.147	1.8
GTEx	Artery Coronary	0	0.000	1.8
GTEx	Brain Cerebellum	2	0.101	1.8
GTEx	Brain Cortex	0	0.000	1.8
GTEx	Brain Frontal Cortex BA9	1	0.108	1.8
GTEx	Brain Hippocampus	1	0.191	1.8
GTEx	Breast Mammary Tissue	3	0.152	1.8
GTEx	Breast Mammary Tissue (Male)	1	0.084	1.8
GTEx	Colon Sigmoid	2	0.137	1.8
GTEx	Colon Transverse	1	0.048	1.8
GTEx	Esophagus Mucosa	4	0.120	1.8
GTEx	Esophagus Muscularis	2	0.062	1.8
GTEx	Heart Atrial Appendage	0	0.000	1.8
GTEx	Heart Left Ventricle	1	0.065	1.8
GTEx	Nerve Tibial	1	0.023	1.8
GTEx	Pancreas	2	0.123	1.8
GTEx	Skin Sun Exposed Lower leg	2	0.055	1.8
GTEx	Spleen	1	0.071	1.8
GTEx	Testis	3	0.095	1.8
GTEx	Thyroid	4	0.100	1.8
GTEx	Uterus	2	0.353	1.8
GTEx	Whole Blood	1	0.050	1.8
The Cancer Genome Atlas	Colon Adenocarcinoma	3	0.145	1.8
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	6	0.146	1.8
The Cancer Genome Atlas	Lung Adenocarcinoma	4	0.136	1.8
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	3	0.120	1.8
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	3	0.181	1.8
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.8
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.8
The Cancer Genome Atlas	Stomach Adenocarcinoma	2	0.119	1.8
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.8
GTEx	Brain Caudate basal ganglia	1	0.109	1.7
GTEx	Brain Cerebellar Hemisphere	0	0.000	1.7
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.7
GTEx	Brain Putamen basal ganglia	1	0.160	1.7
GTEx	Cells EBV-transformed lymphocytes	4	0.281	1.7
GTEx	Pituitary	1	0.090	1.7
GTEx	Small Intestine Terminal Ileum	0	0.000	1.7
METSIM	Adipose	4	0.087	1.7
NTR	Blood	3	0.125	1.7
YFS	Blood	5	0.108	1.7
CommonMind	Brain Pre-frontal Cortex	8	0.149	1.7
The Cancer Genome Atlas	Breast Invasive Carcinoma	8	0.182	1.7
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	2	0.182	1.7
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.7
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	3	0.110	1.7
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	3	0.146	1.7
The Cancer Genome Atlas	Brain Lower Grade Glioma	3	0.070	1.7
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	1	0.090	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	3	0.188	1.7
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	2	0.151	1.7
The Cancer Genome Atlas	Testicular Germ Cell Tumors	1	0.078	1.7
The Cancer Genome Atlas	Thyroid Carcinoma	6	0.116	1.7
GTEx	Brain Hypothalamus	0	0.000	1.6
GTEx	Liver	0	0.000	1.6
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	1	0.060	1.6
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Prostate Adenocarcinoma	5	0.108	1.6
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.6